Amarin Corp Plc (AMRN)

[Biobillionair]

JL- Brilliant insight regarding:

This may have escaped everyones' attention but it has some very significant consequences for the generics...Tier pricing is determined by the cheapest alternative and I believe generic Lovaza will be be able to undercut the generic Vascepa price..And keep in mind that even if generic V can be converted to off label R-I Vascepa..The generics have not won the right to sell the drug for the R-I indication..And if Lovaza can beat Gen Vs price then Gen V will be selling at a higher Tier (ie Tier 3 Or possibly Tier four 4)..And this real possibility could encourage the Generics to settle..as selling the drug without being able to convert to the R-I indication will not be be very profitable.

Thanks
BB/Jas